This week has down with 6 IPOS scheduled for Thursday and Friday.
The company offers a package of over 100 channels, catering to sports fans, at a price point of $59.99 a month. The package includes 43 of the top 50 ranked channels.
In June, the company had 286,126 paid subscribers. Revenue for 2019 was $146.5 million, a 96% year-over-year increase.
Advertising revenue is an area of growth for the company. In 2019, advertising revenue was up 201% year-over-year to $12.5 million. Advertising revenue is expected to hit $6 to $7 per paying customer in the third quarter.
In September, Fubo announced it was seeing strong third-quarter demand from the NFL season. The company now expects paid subscribers of 370,000 to 380,000 in the third quarter.
Aziyo Biologics: Offering implantable medical devices, spinal repair and soft tissue reconstruction, Aziyo Biologics (NASDAQ:AZYO) is a regenerative medicine company. The stock debuted Thursday at $17.32 a share, above the $17 IPO price.
The company has commercial relationships with Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT). The company has four commercial products approved over the last three years and is counting on a robust pipeline to grow approvals and revenue.
The company has seen 222% year-over-year growth in users. iHuman revenue was $30.9 million in 2019 and $26.3 million for the first half six months of 2020.
iHuman plans to offer 7 million ADS at a price point of $11 to $13.
The company is working on the unmet medical need for rare endocrine disorders. The company is targeting classic congenital adrenal hyperplasia with its lead candidate tildacerfront.
Novo Holdings, a unit of Novo Nordisk (NYSE:NVO), is the top shareholder of the company.
The company’s lead product entospletinib is targeting acute myeloid leukemia with a planned Phase 2/3 trial in 2021 and data readouts in 2023.
The company’s lead SL-172154 with a Phase I trial for ovarian cancer. A read-out is expected on this trial in the second half of 2021.
Takeda Pharmaceuticals is partnered with Shattuck on a second candidate named SL-279252 targeting solid tumors and lymphoma.